Journal of Medicinal Chemistry · 2011 · 42 citations · 20 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryNeurochemistryNeuropharmacologyMonoamine NeurochemistryStructure-activity Relationship AnalysisMonoamine Oxidase InhibitionMonoamine Oxidase InhibitorsMonoamine OxidasesMonoamine PharmacologyParkinson's Disease PharmacotherapyParkinson’s Disease Pharmacotherapy
Monoamine oxidases (MAOs) are involved in various psychiatric and neurodegenerative disorders; hence, MAO inhibitors are useful agents in the therapy of Parkinson's disease, Alzheimer's dementia, and depression syndrome. Herein we report a novel series of 3-(1H-pyrrol-3-yl)-2-oxazolidinones 3-7 as reversible, highly potent and selective anti-MAO-A agents. In particular, 4b, 5b, and 4c showed a K(i-MAO-A) of 0.6, 0.8, and 1 nM, respectively, 4c being 200000-fold selective for MAO-A with respect to MAO-B.
20
MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
Jyothi K. Mallajosyula, Deepinder Kaur, Shankar J. Chinta et al. · PLoS ONE · 2008 · 280 citations · Full text